BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22175276)

  • 1. Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays.
    Ramachandran R; Bech P; Murphy KG; Dhillo WS; Meeran KM; Chapman RS; Caplin M; Ghatei MA; Bloom SR; Martin NM
    Clin Endocrinol (Oxf); 2012 Jun; 76(6):831-6. PubMed ID: 22175276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of Chromogranin A in clinical practice.
    Marotta V; Nuzzo V; Ferrara T; Zuccoli A; Masone M; Nocerino L; Del Prete M; Marciello F; Ramundo V; Lombardi G; Vitale M; Colao A; Faggiano A
    Biomarkers; 2012 Mar; 17(2):186-91. PubMed ID: 22303881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
    Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
    Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
    Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
    [No Abstract]   [Full Text] [Related]  

  • 6. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of three chromogranin A assays in patients with neuroendocrine tumours.
    Brehm Hoej L; Parkner T; Soendersoe Knudsen C; Grønbaek H
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):419-24. PubMed ID: 25532001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurements of chromogranin B can serve as a complement to chromogranin A.
    Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
    Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
    Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
    Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
    Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
    Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
    Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia.
    Bech PR; Martin NM; Ramachandran R; Bloom SR
    Ann Clin Biochem; 2014 Jan; 51(Pt 1):8-21. PubMed ID: 23939195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
    Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C
    Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.
    Marotta V; Zatelli MC; Sciammarella C; Ambrosio MR; Bondanelli M; Colao A; Faggiano A
    Endocr Relat Cancer; 2018 Jan; 25(1):R11-R29. PubMed ID: 29066503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays: the importance of protein matrix effects.
    Glinicki P; Kapuścińska R; Jeske W
    Clin Endocrinol (Oxf); 2013 Aug; 79(2):295-6. PubMed ID: 23121682
    [No Abstract]   [Full Text] [Related]  

  • 16. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.
    Modlin IM; Gustafsson BI; Moss SF; Pavel M; Tsolakis AV; Kidd M
    Ann Surg Oncol; 2010 Sep; 17(9):2427-43. PubMed ID: 20217257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of CisBio ELISA for Chromogranin A Measurement.
    Lim M; Erdman P; Cho S; Mathew A; Fleisher M; Thoren KL
    J Appl Lab Med; 2019 Jul; 4(1):11-18. PubMed ID: 31639703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromogranin A: is it a useful marker of neuroendocrine tumors?
    Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
    J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments.
    Korse CM; Taal BG; Vincent A; van Velthuysen ML; Baas P; Buning-Kager JC; Linders TC; Bonfrer JM
    Eur J Cancer; 2012 Mar; 48(5):662-71. PubMed ID: 21945100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.
    Arnold R; Wilke A; Rinke A; Mayer C; Kann PH; Klose KJ; Scherag A; Hahmann M; Müller HH; Barth P
    Clin Gastroenterol Hepatol; 2008 Jul; 6(7):820-7. PubMed ID: 18547872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.